BR112017026535A2 - composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto - Google Patents

composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto

Info

Publication number
BR112017026535A2
BR112017026535A2 BR112017026535A BR112017026535A BR112017026535A2 BR 112017026535 A2 BR112017026535 A2 BR 112017026535A2 BR 112017026535 A BR112017026535 A BR 112017026535A BR 112017026535 A BR112017026535 A BR 112017026535A BR 112017026535 A2 BR112017026535 A2 BR 112017026535A2
Authority
BR
Brazil
Prior art keywords
mct4
monocarboxylate transporter
compound
transporter activity
inhibiting
Prior art date
Application number
BR112017026535A
Other languages
English (en)
Other versions
BR112017026535B1 (pt
Inventor
M Mccall John
Mark Parnell Kenneth
Original Assignee
Vettore Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vettore Llc filed Critical Vettore Llc
Publication of BR112017026535A2 publication Critical patent/BR112017026535A2/pt
Publication of BR112017026535B1 publication Critical patent/BR112017026535B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

são revelados no presente documento os compostos e composições úteis no tratamento de doenças mediadas por mct4, como doenças proliferativas e inflamatórias, que têm a estrutura de fórmula i: (i) métodos de inibição atividade de mct4 em um indivíduo humano ou animal também são fornecidos.
BR112017026535-4A 2015-06-12 2016-06-13 Composto e composição farmacêutica BR112017026535B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562174685P 2015-06-12 2015-06-12
US62/174,685 2015-06-12
PCT/US2016/037213 WO2016201426A1 (en) 2015-06-12 2016-06-13 Mct4 inhibitors for treating disease

Publications (2)

Publication Number Publication Date
BR112017026535A2 true BR112017026535A2 (pt) 2018-08-14
BR112017026535B1 BR112017026535B1 (pt) 2023-12-19

Family

ID=57504734

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026535-4A BR112017026535B1 (pt) 2015-06-12 2016-06-13 Composto e composição farmacêutica

Country Status (12)

Country Link
US (5) US10202350B2 (pt)
EP (2) EP3307068B1 (pt)
JP (2) JP6944442B2 (pt)
KR (1) KR102653599B1 (pt)
CN (1) CN107635404B (pt)
AU (2) AU2016277126A1 (pt)
BR (1) BR112017026535B1 (pt)
CA (1) CA2988983A1 (pt)
ES (1) ES2894919T3 (pt)
HK (1) HK1253239A1 (pt)
IL (2) IL256206A (pt)
WO (1) WO2016201426A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202350B2 (en) 2015-06-12 2019-02-12 Vettore, LLC MCT4 inhibitors for treating disease
MX2019006893A (es) 2016-12-12 2019-10-09 Vettore Llc Inhibidores heterociclicos de mct4.
AU2019317518B2 (en) * 2018-04-25 2023-05-25 Charles R. Drew University Of Medicine And Science Novel MCT4 inhibitors and uses thereof
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
WO2020234454A1 (en) 2019-05-23 2020-11-26 Deutsches Krebsforschungszentrum Combination treatment of cancer targeting energy metabolism and intracellular ph
US20210214731A1 (en) * 2019-10-25 2021-07-15 President And Fellows Of Harvard College Methods for treating cancer
WO2022243574A1 (en) * 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法
WO2023077739A1 (zh) * 2021-11-08 2023-05-11 中国药科大学 一种喹诺酮衍生物及其制备方法和用途
WO2024031445A1 (en) * 2022-08-10 2024-02-15 Vettore, LLC Methods and processes for the preparation of mct4 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
ES2037739T3 (es) 1986-10-22 1993-07-01 Ciba-Geigy Ag Derivados del acido 1,5-difenilpirazol-3-carboxilico para la proteccion de plantas de cultivo.
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
AU2003285503A1 (en) * 2003-11-21 2005-06-24 Astrazeneca Ab Screening method
SG171617A1 (en) 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic compounds
TWI339205B (en) 2006-10-02 2011-03-21 Nat Health Research Institutes Pyrazole compounds and pharmaceutical composition
KR101581828B1 (ko) * 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
CN102093341B (zh) 2009-12-10 2013-07-24 天津药物研究院 吲哚环取代的吡唑羧酸类内皮素受体拮抗剂及其制备方法和用途
EP2606353A4 (en) * 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASE
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
WO2013109972A2 (en) 2012-01-20 2013-07-25 Regents Of The University Of Minnesota Therapeutic compounds
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US9346762B2 (en) * 2012-05-18 2016-05-24 Sanofi Pyrazole derivatives and their use as LPAR5 antagonists
MX2015002038A (es) 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
US20160115146A1 (en) 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
JP7065567B2 (ja) 2014-06-10 2022-05-12 スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用
DE202015003905U1 (de) 2015-06-05 2016-09-12 Rudolf King Methode zur Übermittlung und Differenzierung von Verfassungszuständen während und nach Auslösen eines persönlichen Notfallsystems oder Systems zur Mitteilung an ein soziales Notfallsystem oder Systems zur Mitteilung an ein soziales Notfall-Netzwerk
US20160362056A1 (en) 2015-06-11 2016-12-15 Cequent Performance Products Inc. Roof rack crossbar assembly
US10202350B2 (en) 2015-06-12 2019-02-12 Vettore, LLC MCT4 inhibitors for treating disease
MX2019006893A (es) 2016-12-12 2019-10-09 Vettore Llc Inhibidores heterociclicos de mct4.

Also Published As

Publication number Publication date
US20160362378A1 (en) 2016-12-15
BR112017026535B1 (pt) 2023-12-19
CN107635404B (zh) 2021-09-28
KR20180012852A (ko) 2018-02-06
CA2988983A1 (en) 2016-12-15
IL278247B (en) 2021-12-01
AU2021200919A1 (en) 2021-03-04
AU2021200919B2 (en) 2022-06-30
CN107635404A (zh) 2018-01-26
US20210009524A1 (en) 2021-01-14
AU2016277126A1 (en) 2017-12-14
US20220251045A1 (en) 2022-08-11
JP2018516994A (ja) 2018-06-28
US11724989B2 (en) 2023-08-15
JP6944442B2 (ja) 2021-10-06
NZ738078A (en) 2021-11-26
EP3942934A1 (en) 2022-01-26
US20240101518A1 (en) 2024-03-28
EP3307068A1 (en) 2018-04-18
US20190112274A1 (en) 2019-04-18
JP2021152056A (ja) 2021-09-30
US10202350B2 (en) 2019-02-12
US11155522B2 (en) 2021-10-26
KR102653599B1 (ko) 2024-04-01
EP3307068B1 (en) 2021-08-25
EP3307068A4 (en) 2018-12-26
ES2894919T3 (es) 2022-02-16
HK1253239A1 (zh) 2019-06-14
WO2016201426A1 (en) 2016-12-15
IL256206A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
CO2017011851A2 (es) Compuestos novedosos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016001895A1 (es) Compuestos
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
BR112017010166A2 (pt) método de tratamento de um tumor sólido, método de inibição da atividade, forma de dosagem oral para o tratamento de um tumor sólido, formulação farmacêutica sólida, processo para a preparação de uma formulação farmacêutica, e, composição farmacêutica sólida
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112017002369A2 (pt) derivados de diazepana e usos dos mesmos
BR112016030730A8 (pt) composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/56

Ipc: A61K 31/415 (2006.01), A61K 31/4155 (2006.01), A61

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2016, OBSERVADAS AS CONDICOES LEGAIS